GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (LTS:0W4N) » Definitions » Debt-to-Revenue

Formycon AG (LTS:0W4N) Debt-to-Revenue : 0.12 (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Formycon AG Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Formycon AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €1.50 Mil. Formycon AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €9.10 Mil. Formycon AG's annualized Revenue for the quarter that ended in Dec. 2024 was €85.56 Mil. Formycon AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 0.12.


Formycon AG Debt-to-Revenue Historical Data

The historical data trend for Formycon AG's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Debt-to-Revenue Chart

Formycon AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.14 0.69 0.38 0.15

Formycon AG Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.10 0.44 0.20 0.12

Competitive Comparison of Formycon AG's Debt-to-Revenue

For the Biotechnology subindustry, Formycon AG's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Formycon AG's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Formycon AG's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Formycon AG's Debt-to-Revenue falls into.


;
;

Formycon AG Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Formycon AG's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.496 + 9.097) / 69.674
=0.15

Formycon AG's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(1.496 + 9.097) / 85.562
=0.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2024) Revenue data.


Formycon AG Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Formycon AG's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Formycon AG Headlines

No Headlines